

Cytokinetics, Incorporated
Condensed Consolidated Statements of Operations
(in thousands, except per share data)
(unaudited)

	Three Months Ended	
	March 31, 2015	March 31, 2014
Revenues:		
Research and development revenues from related parties	\$ 2,791	\$ 665
Research and development, grant and other revenues	—	5,232
License revenues from related parties	1,623	—
License revenues	—	2,082
Total revenues	4,414	7,979
Operating Expenses:		
Research and development	8,956	12,490
General and administrative	4,367	4,259
Total operating expenses	13,323	16,749
Operating loss	(8,909)	(8,770)
Interest and other, net	37	26
Net loss	\$ (8,872)	\$ (8,744)
Net loss per share – basic and diluted	\$ (0.23)	\$ (0.27)
Weighted average shares used in computing net loss per share - basic and diluted	38,675	32,985

Cytokinetics, Incorporated
Condensed Consolidated Balance Sheets
(in thousands)

	<u>March 31,</u> <u>2015</u>	<u>December 31,</u> <u>2014⁽¹⁾</u>
	(unaudited)	
Assets		
Cash and cash equivalents	\$ 22,546	\$ 20,215
Short-term investments	85,322	63,013
Related party accounts receivable	970	46,646
Prepaid and other current assets	<u>1,972</u>	<u>1,257</u>
Total current assets	110,810	131,131
Property and equipment, net	1,551	1,637
Long-term investments	9,653	—
Other assets	<u>200</u>	<u>200</u>
Total assets	<u>\$ 122,214</u>	<u>\$ 132,968</u>
Liabilities and stockholders' equity		
Deferred revenue, current	\$ 19,942	\$ 17,042
Other current liabilities	5,443	6,813
Total current liabilities	<u>25,385</u>	<u>23,855</u>
Deferred revenue, non-current	12,211	16,558
Other non-current liabilities	466	491
Stockholders' equity	<u>84,152</u>	<u>92,064</u>
Total liabilities and stockholders' equity	<u>\$ 122,214</u>	<u>\$ 132,968</u>

⁽¹⁾ Derived from the audited financial statements, included in the Company's Annual Report on Form 10-K for the year ended December 31, 2014.